The loss or downregulation of TGFbi (a tumor suppressor) is related to lung cancer, breast cancer, and ovarian cancers [33,34,35], whereas overexpression (a tumor promoter) is associated with pancreatic, colorectal, and other gastrointestinal malignancies [36,37,38]. Here, TGFBI is linked to breast carcinoma.